Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11876338 | 1.00 | MDM2 (0.53) | MDM2PGRADRA2AADRA2BHTR2A | |
| SCHEMBL1704486 | 0.88 | MDM2 (0.61) | MDM2PGRADRA2AADRA2BHTR2A | |
| SCHEMBL442090 | 0.86 | MDM2 (0.59) | MDM2PGRADRA2AADRA2BHTR2A | |
| Fluoride SCHEMBL28046161 | 0.84 | MDM2 (0.57) | MDM2PGRADRA2AADRA2BHTR2A | |
| SCHEMBL8882147 | 0.82 | MDM2 (0.55) | MDM2PGRADRA2AADRA2BHTR2A | |
| SCHEMBL3163300 | 0.82 | MDM2 (0.55) | MDM2PGRADRA2AADRA2BHTR2A | |
| SCHEMBL5706319 | 0.81 | MDM2 (0.53) | MDM2PGRADRA2AADRA2BHTR2A | |
| SCHEMBL4871573 | 0.81 | MDM2 (0.53) | MDM2PGRADRA2AADRA2BHTR2A | |
| SCHEMBL4871582 | 0.81 | MDM2 (0.53) | MDM2PGRADRA2AADRA2BHTR2A | |
| SCHEMBL17433635 | 0.79 | MDM2 (0.52) | MDM2PGRADRA2AADRA2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1507765-A4 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INST BIOLOG RES (IL) | 2006-11-02 | — | — | EP | claimed |
| EP-1507765-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2005-02-23 | — | — | EP | claimed |
| WO-2003092580-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2003-11-13 | — | — | WO | claimed |
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2008-12-11 | — | — | US | disclosed |
| US-7439251-B2 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2008-10-21 | — | — | US | disclosed |
| EP-1507765-A4 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INST BIOLOG RES (IL) | 2006-11-02 | — | — | EP | disclosed |
| US-7049321-B2 | Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2006-05-23 | — | — | US | disclosed |
| US-20060052406-A1 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | ISREAL INSTITUTE FOR BIOLOGICAL RESEARCH (US) | 2006-03-09 | — | — | US | disclosed |
| EP-1507765-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2005-02-23 | — | — | EP | disclosed |
| US-20040044018-A1 | Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2004-03-04 | — | — | US | disclosed |
| WO-2003092580-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | PMP22, PYGB, GAP43 | MDM2 4581/4885PGR 2163/4885ADRA2A 898/4885 |
| US-20040044018-A1 | Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor | PMP22, PYGB, GAP43 | MDM2 4461/4885PGR 1715/4885ADRA2A 819/4885 |
| US-20060052406-A1 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | PMP22, PYGB, GAP43 | MDM2 4581/4885PGR 2163/4885ADRA2A 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.